|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SDR16C5 |
Gene summary for SDR16C5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SDR16C5 | Gene ID | 195814 |
| Gene name | short chain dehydrogenase/reductase family 16C member 5 | |
| Gene Alias | EPHD-2 | |
| Cytomap | 8q12.1 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | B3KT84 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 195814 | SDR16C5 | HTA11_2487_2000001011 | Human | Colorectum | SER | 6.07e-05 | 2.84e-01 | -0.1808 |
| 195814 | SDR16C5 | HTA11_1938_2000001011 | Human | Colorectum | AD | 5.67e-06 | 2.72e-01 | -0.0811 |
| 195814 | SDR16C5 | HTA11_411_2000001011 | Human | Colorectum | SER | 9.67e-06 | 6.74e-01 | -0.2602 |
| 195814 | SDR16C5 | HTA11_2112_2000001011 | Human | Colorectum | SER | 7.60e-05 | 5.95e-01 | -0.2196 |
| 195814 | SDR16C5 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.78e-04 | 1.91e-01 | 0.0588 |
| 195814 | SDR16C5 | LZE5T | Human | Esophagus | ESCC | 1.70e-02 | 5.45e-01 | 0.0514 |
| 195814 | SDR16C5 | LZE20T | Human | Esophagus | ESCC | 2.24e-21 | 1.06e+00 | 0.0662 |
| 195814 | SDR16C5 | LZE24T | Human | Esophagus | ESCC | 1.64e-10 | 4.77e-01 | 0.0596 |
| 195814 | SDR16C5 | P1T-E | Human | Esophagus | ESCC | 5.43e-10 | 9.38e-01 | 0.0875 |
| 195814 | SDR16C5 | P2T-E | Human | Esophagus | ESCC | 1.47e-04 | 9.32e-02 | 0.1177 |
| 195814 | SDR16C5 | P4T-E | Human | Esophagus | ESCC | 7.51e-09 | 3.47e-01 | 0.1323 |
| 195814 | SDR16C5 | P5T-E | Human | Esophagus | ESCC | 2.00e-26 | 6.69e-01 | 0.1327 |
| 195814 | SDR16C5 | P8T-E | Human | Esophagus | ESCC | 1.53e-04 | 1.04e-01 | 0.0889 |
| 195814 | SDR16C5 | P10T-E | Human | Esophagus | ESCC | 3.41e-10 | 2.00e-01 | 0.116 |
| 195814 | SDR16C5 | P12T-E | Human | Esophagus | ESCC | 8.88e-20 | 3.31e-01 | 0.1122 |
| 195814 | SDR16C5 | P15T-E | Human | Esophagus | ESCC | 2.25e-02 | 3.69e-02 | 0.1149 |
| 195814 | SDR16C5 | P16T-E | Human | Esophagus | ESCC | 9.14e-03 | 3.16e-02 | 0.1153 |
| 195814 | SDR16C5 | P20T-E | Human | Esophagus | ESCC | 1.28e-04 | 1.09e-01 | 0.1124 |
| 195814 | SDR16C5 | P21T-E | Human | Esophagus | ESCC | 3.91e-47 | 1.00e+00 | 0.1617 |
| 195814 | SDR16C5 | P23T-E | Human | Esophagus | ESCC | 8.19e-51 | 1.84e+00 | 0.108 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006066 | Colorectum | AD | alcohol metabolic process | 106/3918 | 353/18723 | 3.02e-05 | 5.57e-04 | 106 |
| GO:0050673 | Colorectum | AD | epithelial cell proliferation | 119/3918 | 437/18723 | 8.75e-04 | 8.51e-03 | 119 |
| GO:0034308 | Colorectum | AD | primary alcohol metabolic process | 35/3918 | 102/18723 | 1.16e-03 | 1.05e-02 | 35 |
| GO:0043616 | Colorectum | AD | keratinocyte proliferation | 19/3918 | 46/18723 | 1.36e-03 | 1.19e-02 | 19 |
| GO:0006081 | Colorectum | AD | cellular aldehyde metabolic process | 22/3918 | 60/18723 | 3.64e-03 | 2.60e-02 | 22 |
| GO:0031056 | Colorectum | AD | regulation of histone modification | 45/3918 | 152/18723 | 7.05e-03 | 4.31e-02 | 45 |
| GO:00060661 | Colorectum | SER | alcohol metabolic process | 79/2897 | 353/18723 | 3.50e-04 | 5.50e-03 | 79 |
| GO:1901984 | Colorectum | SER | negative regulation of protein acetylation | 10/2897 | 24/18723 | 1.88e-03 | 1.90e-02 | 10 |
| GO:00310561 | Colorectum | SER | regulation of histone modification | 37/2897 | 152/18723 | 2.80e-03 | 2.50e-02 | 37 |
| GO:00343081 | Colorectum | SER | primary alcohol metabolic process | 26/2897 | 102/18723 | 5.87e-03 | 4.29e-02 | 26 |
| GO:2000757 | Colorectum | SER | negative regulation of peptidyl-lysine acetylation | 8/2897 | 20/18723 | 7.14e-03 | 4.99e-02 | 8 |
| GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
| GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
| GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
| GO:001839313 | Esophagus | ESCC | internal peptidyl-lysine acetylation | 114/8552 | 158/18723 | 1.16e-11 | 4.24e-10 | 114 |
| GO:000647513 | Esophagus | ESCC | internal protein amino acid acetylation | 115/8552 | 160/18723 | 1.43e-11 | 5.08e-10 | 115 |
| GO:00165735 | Esophagus | ESCC | histone acetylation | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| GO:003105614 | Esophagus | ESCC | regulation of histone modification | 106/8552 | 152/18723 | 1.52e-09 | 3.55e-08 | 106 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa012405 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
| hsa0124012 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
| hsa012404 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
| hsa0124011 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
| hsa0124021 | Oral cavity | LP | Biosynthesis of cofactors | 57/2418 | 153/8465 | 1.17e-02 | 3.91e-02 | 2.52e-02 | 57 |
| hsa0124031 | Oral cavity | LP | Biosynthesis of cofactors | 57/2418 | 153/8465 | 1.17e-02 | 3.91e-02 | 2.52e-02 | 57 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SDR16C5 | SNV | Missense_Mutation | novel | c.199N>G | p.Leu67Val | p.L67V | protein_coding | tolerated(0.23) | benign(0.389) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD | |
| SDR16C5 | SNV | Missense_Mutation | c.91N>T | p.Leu31Phe | p.L31F | protein_coding | tolerated(0.39) | benign(0.009) | TCGA-A1-A0SE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SDR16C5 | SNV | Missense_Mutation | c.263N>A | p.Gly88Glu | p.G88E | protein_coding | deleterious(0.01) | probably_damaging(0.977) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| SDR16C5 | SNV | Missense_Mutation | novel | c.587N>A | p.Ala196Glu | p.A196E | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SDR16C5 | SNV | Missense_Mutation | novel | c.878N>A | p.Ala293Asp | p.A293D | protein_coding | tolerated(0.21) | benign(0.007) | TCGA-AC-A8OR-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SDR16C5 | SNV | Missense_Mutation | c.754N>A | p.Glu252Lys | p.E252K | protein_coding | tolerated(0.98) | benign(0.006) | TCGA-AR-A0TZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Doxorubicin | PD | ||
| SDR16C5 | SNV | Missense_Mutation | c.694N>C | p.Glu232Gln | p.E232Q | protein_coding | tolerated(0.08) | benign(0.132) | TCGA-PL-A8LV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| SDR16C5 | SNV | Missense_Mutation | c.659N>C | p.Ile220Thr | p.I220T | protein_coding | deleterious(0.03) | benign(0.274) | TCGA-EK-A2PM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SDR16C5 | SNV | Missense_Mutation | c.775N>A | p.Leu259Ile | p.L259I | protein_coding | deleterious(0.01) | probably_damaging(0.936) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | ||
| SDR16C5 | SNV | Missense_Mutation | rs371326324 | c.280G>A | p.Ala94Thr | p.A94T | protein_coding | tolerated(0.54) | benign(0.031) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |